Explore Our Clinical Trials

Currently, obefazimod is being tested in a Phase 3 program (known as ABTECT) in adults with moderately to severely active ulcerative colitis (UC). Based on the successful Phase 2 trials in UC, a Phase 2b trial in Crohn’s disease is also planned, with enrollment expected to start in Q3 2024.

Upcoming Clinical Trials

Abivax will conduct a dose-ranging Phase 2b clinical trial in moderately to severely active Crohn’s disease. The start of patient enrollment is planned for Q3 2024.

Completed Phase 2 Trials

A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Dose, Induction Study to Evaluate the Safety, Tolerability and Optimal Dose of Obefazimod (ABX464)

Compared With Placebo in Patients With Moderate to Severe Ulcerative Colitis Who Have Inadequate Response, Loss of Response, or Intolerance With at Least One of the Following Agents: Immunosuppressant Treatment (i.e. Azathioprine, 6-mercaptopurine, Methotrexate), Tumor Necrosis Factor Alpha [TNF-α] Inhibitors, Vedolizumab, JAK Inhibitors and/or Corticosteroid Treatment

Actual Enrollment: N=254
Completed 2021

Join the ABTECT Trial Program

Abivax is currently recruiting trial participants for the Phase 3 program investigating its lead drug candidate, obefazimod.*


*Abivax does not determine the eligibility of patients enrolled into the ABTECT program.